Peptide Dosage Guide: Doses From Human Studies

When researchers study a new peptide, they begin with cell cultures and animal models. These early experiments help establish basic safety and receptor binding, but they do not provide a dose that can be transferred directly to people.

A dose that produces a specific effect in a rodent might be ineffective or unsafe in a human. For this reason, scaling an animal dose by body weight or surface area does not produce a valid human dose. The only reliable source for human dosing is a published human clinical trial or a regulator approved product label.

How human doses are determined in trials

Phase 1 trials begin with healthy volunteers to measure pharmacokinetics. This includes absorption, distribution, metabolism and excretion. A peptide's half life determines how long it remains active in the blood, while its volume of distribution indicates how widely it spreads into tissues.

Researchers take frequent blood samples to map exactly how the peptide concentration rises and falls over time.

Phase 2 trials then compare a range of doses in patients with the target condition, and this is where titration schedules for long acting metabolic peptides were refined. Phase 3 trials then test selected doses in thousands of patients across multiple clinical centres. These large scale studies confirm whether the dose is effective in a diverse population and whether rare side effects emerge. Even after a drug is approved, post market surveillance continues to monitor the safety of the established dose in the general public. The final doses seen on product labels are the direct result of these extensive dose finding studies, not theoretical calculations.

Semaglutide and the need for titration

Some peptide medicines require careful management of tolerability. Semaglutide is a long acting GLP-1 receptor agonist. The STEP 1 clinical trial evaluated semaglutide for chronic weight management in adults. Researchers evaluated 68 weeks of treatment with once weekly subcutaneous semaglutide at a dose of 2.4 mg. Human ¹

In the trial, nausea and diarrhoea were the most common adverse events, which were typically transient and mild to moderate, though more participants receiving semaglutide discontinued treatment due to gastrointestinal events compared to placebo. Human ¹

Tirzepatide uses a stepwise escalation

Tirzepatide is a once weekly GIP and GLP-1 receptor agonist, and it too is started low and increased in steps to manage gastrointestinal effects. Human ²

The SURMOUNT-1 clinical trial tested three once weekly maintenance doses of tirzepatide: 5 mg, 10 mg, and 15 mg. Participants received once weekly subcutaneous tirzepatide for 72 weeks, which included a 20-week dose escalation period. Human ²

The trial found that all three doses provided substantial and sustained reductions in body weight, with the 15 mg dose providing the greatest reduction. The most common adverse events were gastrointestinal, occurring primarily during dose escalation. Human ²

Research peptides with no established human dose

Many popular research peptides, including BPC-157 and TB-500, have no established human dose. They do not have approved product labels, and there are no large scale, published human trials defining a safe or effective dosing regimen.

When vendors or forums list specific doses for these experimental molecules, those numbers are not derived from clinical evidence. They are typically estimates, guesses or direct conversions from animal studies. Without human pharmacokinetic data, it is impossible to know how much of the peptide is absorbed, how long it remains active, or what concentration is required to achieve a biological effect in people.

Using an unverified dose carries unknown risks. A dose that appears safe in a rodent might cause unexpected side effects or immune responses in a human. Experimental peptides also often lack the rigorous quality control of approved medicines. An unverified dose combined with unknown purity creates a highly unpredictable safety profile. Until a compound completes formal human trials, any dosing protocol remains entirely experimental.

UK regulation and anti doping rules

The legal status of peptide medicines depends entirely on their regulatory approval. In the UK, the MHRA is the executive agency responsible for regulating medicines and medical devices. ³

Before a peptide can be legally sold or supplied as a medicine, it must undergo strict clinical evaluation. The law is clear on this requirement. ⁴

Companies wishing to market a peptide therapy must submit comprehensive safety, efficacy and manufacturing data to the regulator. ⁵

Experimental peptides that lack this authorisation cannot be legally sold as medicines. In sport, the World Anti-Doping Agency prohibits at all times any pharmacological substance that no other section of its list covers and that has no current approval from a government health authority for human therapeutic use. ⁶

The BioRx conclusion

Peptide doses cannot be guessed or scaled from animal research. The exact milligram amounts and titration schedules used in clinical practice are the result of extensive human trials designed to balance efficacy with tolerability. Human ^{1 2}

For experimental compounds, no human dose has been established, and any protocols found online remain unverified by clinical data.

Frequently asked questions

Why do some peptides require titration?

Some peptides, particularly long acting GLP-1 and GIP receptor agonists, can cause gastrointestinal side effects if started at a high dose. Titration allows the body to adapt to the receptor activation gradually over several weeks or months.

Can animal doses be converted to human doses?

No. A dose that is effective in a rodent cannot be reliably scaled to a human by body weight or surface area.

How often are peptides administered?

Administration frequency depends entirely on the molecule's half life. Some engineered peptides are designed to last for days and are dosed once weekly, while natural or shorter acting peptides may require daily administration.

Are research peptides approved for human use?

Most research peptides sold online do not have regulatory approval for human use. Compounds without a marketing authorisation have not completed the necessary clinical trials to establish a safe dose, efficacy profile or manufacturing standard.

More peptide questions

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
2. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
3. MHRA, the Medicines and Healthcare products Regulatory Agency
4. Human Medicines Regulations 2012, regulation 46: a medicinal product needs a marketing authorisation to be sold or supplied
5. MHRA guidance: apply for a licence to market a medicine in the UK
6. WADA, Prohibited List